CVID participants
| Parameters . | N . |
|---|---|
| Number of CVID patients | 408 |
| Males | 219 |
| Females | 189 |
| Median age, years (range) | 44 (5-77) |
| Relatives with known immune defects | 26 |
| IgG* (86-1, 602 mg/dL) | 6-594 mg/dL (mean 272.5 +/-166.6.2) |
| IgA (87-352 mg/dL) | 0-174 mg/dL (mean 19.44+/-29.01) |
| IgM (26-217 mg/dL) | 0-801 mg/dL (mean 42.25 +/-85.56) |
| Patients with hematologic autoimmunity | 122 (30%) Females = 62; males = 60 |
| Patients without hematologic autoimmunity | 286 (70%) Females = 140; males = 149 |
| Parameters . | N . |
|---|---|
| Number of CVID patients | 408 |
| Males | 219 |
| Females | 189 |
| Median age, years (range) | 44 (5-77) |
| Relatives with known immune defects | 26 |
| IgG* (86-1, 602 mg/dL) | 6-594 mg/dL (mean 272.5 +/-166.6.2) |
| IgA (87-352 mg/dL) | 0-174 mg/dL (mean 19.44+/-29.01) |
| IgM (26-217 mg/dL) | 0-801 mg/dL (mean 42.25 +/-85.56) |
| Patients with hematologic autoimmunity | 122 (30%) Females = 62; males = 60 |
| Patients without hematologic autoimmunity | 286 (70%) Females = 140; males = 149 |
Reference ranges for adults.